The Blood Test That Found Cancer 7x Better, Then Tanked 47%
Grail's Galleri blood test detected deadly cancers at seven times the normal rate and cut Stage IV diagnoses by over 20%. The stock still crashed 47% because the trial's own design masked the very success it was measuring.
Imagine acing every question on a test, and still failing the class because the grading rubric was broken.
That's essentially what just happened to Grail's Galleri blood test, the most ambitious cancer screening tool ever built. The results from the largest randomized trial of a multi-cancer blood test came in last week, and the data looked genuinely impressive. Galleri detected cancers at seven times the rate of standard screening. It caught nearly three-quarters of the 12 deadliest cancer types. It held false positives to a razor-thin 0.4%.
And the stock still cratered 47% after hours.
Welcome to one of the most confusing days in cancer screening history.
The Trial That Was Supposed to Change Everything
The NHS-Galleri trial was a massive bet. Over 142,000 people in the UK, aged 50 to 77, were enrolled in a double-blind randomized study, the gold standard of medical evidence. Half got the Galleri blood test on top of their regular cancer screenings. The other half just got standard care. Participants gave blood samples three times over two years, roughly a year apart.
The concept behind Galleri is elegant. Instead of screening for one cancer at a time (mammograms for breast, colonoscopies for colon), Galleri looks for DNA methylation patterns, chemical signatures that cancer cells shed into your bloodstream. It can detect signals from over 50 cancer types in a single blood draw and even predict where in the body the cancer is coming from.
Think of it like a smoke detector for your entire house, instead of one that only covers the kitchen.
The trial was designed to answer a simple question: if you screen people with Galleri, do fewer of them get diagnosed with late-stage cancer? Because catching cancer early, before it spreads and becomes untreatable, is the whole ballgame.
The Endpoint That Ruined the Party
The trial's primary endpoint was a statistically significant reduction in combined Stage III and Stage IV cancer diagnoses. That's the number the entire study was built around. Hit it, and you've got a landmark result. Miss it, and you get a 47% stock crash.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
Grail missed it.
But the reason why they missed it is where this story gets genuinely interesting, and genuinely frustrating.
The trial lumped Stage III and Stage IV together into one bucket. On the surface, that seems reasonable — both are "late-stage." But in practice, it's like grading a restaurant by combining the appetizers and the desserts into one score. They're related, but they tell you very different things.
Stage III cancers are serious. They've often spread to nearby lymph nodes. But many Stage III cancers are still treatable, even curable. Stage IV is a different beast entirely. That's when cancer has metastasized, spread to distant organs. For many cancer types, Stage IV is where survival rates plummet.
What the trial actually found was a higher-than-expected number of Stage III diagnoses in the Galleri group. That sounds bad until you think about what it means. The test was finding Stage III cancers that would have otherwise gone undetected and progressed to Stage IV. It was doing exactly what a screening tool should do, catching danger before it becomes a death sentence.
The Number That Actually Matters
Bury yourself in the secondary data and a very different story emerges.
Stage IV diagnoses, the cancers most likely to kill you, dropped by more than 20% in the second and third screening rounds for the 12 deadliest cancer types. These are cancers like pancreatic, lung, and esophageal, the ones that rarely get caught early by any existing screening method and account for roughly two-thirds of cancer deaths in the UK and US.
Let that sink in. A simple blood test reduced the rate of the most lethal cancer diagnoses by over a fifth. At the same time, Stage I and Stage II detections went up, meaning more cancers were being found when they were still manageable.
The overall cancer detection rate was four times higher when Galleri was added to standard screening. The test's accuracy matched what earlier North American studies had shown. No serious safety issues were reported. The false-positive rate was vanishingly low.
By almost every measure that matters to a patient, Galleri worked. The problem is that the one measure the trial was officially designed around, the combined Stage III-IV number, got muddied by the very success of early detection. Galleri caught so many Stage III cancers that the combined late-stage bucket actually looked flat, even though Stage IV was declining.
It's the statistical equivalent of a seesaw. One end went up precisely because the other end was going down.
Wall Street Didn't Read Past the Headline
The market's reaction was swift and brutal. Grail's stock went from $101.53 to roughly $49.66 in after-hours trading, with over 3.4 million shares changing hands. Securities-law firms started circling. The headlines all said the same thing: "Trial Failed."
But several analysts pushed back. Canaccord cut its price target from $105 to $80 but maintained a Buy rating, calling the roughly 50% drop an "overreaction." Baird trimmed to $82 from $113 while keeping an Outperform rating. Even at the slashed prices, these targets imply significant upside from where the stock landed.
Grail's financials tell a story of a company that's not going anywhere. Q4 2025 revenue came in at $43.6 million, beating estimates. U.S. Galleri revenue grew 26% year-over-year to $136.8 million, with over 185,000 tests sold. The company is sitting on $904 million in cash, enough runway to operate into 2030.
Retail investors on Stocktwits flipped to "extremely bullish" after the crash. Sometimes the crowd sees what the algorithms miss.
Why the Measuring Stick Was Broken
Several experts have questioned whether the trial's primary endpoint was the right yardstick in the first place.
Biostatistician Ruth Etzioni has suggested the trial may have been too short to capture the full signal. Eric Topol has argued that enrolling high-risk patients rather than a general population would have given the study more statistical power to detect a meaningful difference.
The National Cancer Institute has long maintained that mortality reduction, not stage shift, is the true gold standard for cancer screening trials. But mortality data takes years, sometimes decades, to mature. Stage shift was chosen as a pragmatic surrogate, a shortcut. The problem is that combining Stage III and IV into one endpoint created a shortcut that pointed in the wrong direction.
Full stage-specific data is expected at the ASCO 2026 Annual Meeting later this year. That presentation could fundamentally reshape how the market, and regulators, interpret these results.
The FDA Is Already Watching
Grail submitted its final FDA Premarket Approval application on January 29, 2026, just three weeks before the NHS trial results dropped. The submission leans on data from both the PATHFINDER 2 study (roughly 25,500 U.S. adults) and the first-year results from NHS-Galleri. Galleri has carried FDA Breakthrough Device designation since 2018, which could speed up the review process.
The test has been commercially available since 2021 as a lab-developed test, priced around $949. But without FDA approval, insurance coverage has been limited. An FDA nod would open the door to a potential CMS coverage decision, which could make Galleri accessible to millions of Medicare patients.
The NHS trial results complicate the regulatory picture, but they don't necessarily doom it. The FDA's PMA submission specifically focuses on Stages I-III detection benefit and Stage IV reduction, exactly the areas where Galleri showed strength. If the agency looks at the full data set rather than just the primary endpoint headline, there's a real case to be made.
What This Means for Cancer Screening
Grail is currently the only company with a multi-cancer blood test backed by a large-scale randomized controlled trial. Competitors like Guardant Health (focused on colorectal cancer with its Shield test) and Exact Sciences (Cologuard, also colorectal) are playing in narrower lanes. Freenome is still in clinical trials with its own blood-based colorectal test. None of them are screening for 50+ cancers simultaneously.
But the NHS-Galleri trial raises questions that extend far beyond Grail. If the leading multi-cancer screening test can deliver a 20%-plus reduction in Stage IV diagnoses and still technically "fail" its trial, something is wrong with how we define success.
Cancer screening has always been measured in stages and survival curves. These results suggest we might need better metrics, ones that account for the unique dynamics of a test that catches dozens of cancer types at once, some of which inevitably get found at Stage III precisely because they'd otherwise show up at Stage IV.
The test worked. The measuring stick didn't. And now an entire field has to decide whether to keep using the old ruler or build a new one.
Full data at ASCO this summer will tell us more. But from where things stand today, Galleri's biggest enemy wasn't the biology. It was the trial design. And that might be the most fixable problem in all of oncology.
Clinical and Regulatory
4 min read
Roche's New Breast Cancer Pill Has a Secret Weapon
Roche's oral breast cancer drug giredestrant just got its FDA date, and its secret weapon isn't the drug itself. It's the combination strategy that cut disease progression by 62% in the patients who need it most.
